BioCentury | Dec 12, 2019
Financial News

Trio of follow-ons lift 2019 tally of deals

December’s rush of follow-ons has continued with Rocket, Constellation and Marinus all pricing follow-on offerings since Tuesday’s close to raise more than $340 million. But cash raised via follow-ons continues to lag behind last year's...
BioCentury | Dec 10, 2019
Clinical News

Dec. 9 ASH Quick Takes: Kite, Principia, Blueprint, Precision and Rocket

Kite plans marketing applications for CD19 CAR T on pivotal MCL data Kite Pharma Inc. reported a 93% best objective response rate including a 67% complete response rate -- secondary endpoints -- in 60 evaluable...
BioCentury | Aug 5, 2019
Clinical News

Aug. 5 Clinical Quick Takes: Emgality meets for migraine with treatment failures; plus Verona, Alkahest-Grifols, Squarex and Denali-Sanofi

Emgality meets in Phase III in pretreated migraine patients Eli Lilly and Co. (NYSE:LLY) reported that anti-CGRP mAb Emgality galcanezumab-gnlm met the primary endpoint in the Phase III CONQUER trial, reducing migraine headache days by...
BioCentury | Jan 25, 2019
Clinical News

Verona's ensifentrine misses in Phase II for COPD maintenance

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said both doses of ensifentrine (RPL554) given on top of dual bronchodilator therapy missed the primary endpoint in a Phase II trial as maintenance treatment of chronic obstructive pulmonary disease...
BioCentury | Nov 30, 2018
Financial News

Follow-on roundup: Acadia raises $275M, Rocket pockets $55M

CNS company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and gene therapy company Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) each priced follow-ons late Nov. 27, raising $275 million and $55 million, respectively. Acadia markets Nuplazid pimavanserin, a small molecule serotonin...
BioCentury | Nov 28, 2018
Financial News

Follow-on roundup: Acadia raises $275M, Rocket pockets $55M

CNS company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and gene therapy company Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) each priced follow-ons late Tuesday, raising $275 million and $55 million, respectively. Acadia markets Nuplazid pimavanserin, a small molecule serotonin receptor...
BioCentury | Mar 30, 2018
Clinical News

Verona's RPL554 meets in Phase IIb for COPD

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIb trial in 403 patients with moderate to severe chronic obstructive pulmonary disease (COPD) showing that all four doses of RPL554 (VMX554, VRP554) as...
BioCentury | Mar 23, 2018
Clinical News

Verona reports Phase IIa data for RPL554 in CF

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIa trial in 10 cystic fibrosis patients showing that single doses of 1.5 and 6 mg RPL554 (VMX554, VRP554) both significantly increased mean forced...
BioCentury | Oct 13, 2017
Clinical News

Verona reports Phase IIa data for RPL554 in COPD

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIa trial in patients with chronic obstructive pulmonary disease (COPD) showing that twice-daily 1.5 and 6 mg doses of RPL554 (VMX554, VRP554) plus Spiriva...
BioCentury | Jun 9, 2017
Clinical News

Verona begins PK trial for RPL554 in healthy volunteers

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) began a 2-way crossover, U.S. trial to evaluate the bioavailability, pharmacokinetics and safety of nebulized RPL554 in 12 healthy volunteers. Data from the trial are expected in 4Q17. The nebulized...
Items per page:
1 - 10 of 41